The Management of Breast Cancer
Part II
3/22/2013
Gary M. Freedman, M.D.Associate Professor
2
Outlinew Positive nodes in the breast conservation patient.w Risk factors for local-regional recurrence after mastectomy.w Regional nodal radiation therapy.w Breast conservation and radiation after neoadjuvant
chemotherapy.w Indications for radiation after neoadjuvant chemotherapy and
mastectomy.w Radiation therapy for locally advanced noninflammatory
breast cancer.w Radiation therapy for inflammatory breast cancer.
Positive nodes in the breast conservation patient
4
BCS + RT: Node Positivew NSABP B04: Variations of axillary nodal treatmentw No differences in survival
Fisher et al NEJM 2002;347:567-75.
5
BCS + RT: Node Positive
Fisher et al Surg Gyn Obstet 1981;152:765-72.
w NSABP B04: Variations of axillary node treatment
6
BCS + RT: Node Positivew NSABP B-06 – No PMRT, and breast only without nodal RT
Fisher et al N Engl J Med 2002; 347:1233-41.
7
BCS + RT: Node Positivew Vicini 1997w Regional node recurrence rare for N0-3 with breast RT alone.
Vicini et al Int J Radiat Oncol Biol Phys 1997; 39:1069-76.
8
BCS + RT: Node Positivew Galper 1999w BCS + Whole Breast Radiation. w No Regional Radiation.w Isolated regional node recurrences at 8 years:
• S’clav 1.3%, axilla 1.2%, infraclav 0.4% and IMN 0.3%
Galper et al Int J Radiat Oncol Biol Phys 1999; 45:1157-66.
9
BCS + RT: Node Positive
Wapnir et al J Clin Oncol 2006; 24:2028-37.
w NSABPw 2/3 1-3 + nodes, 1/3 4 or more + nodes.w BCS + Whole Breast Radiation. No Regional Radiation.
10
BCS + RT: Undissected Axillaw Wong 2008w BCS + Whole Breast Radiation.w No Axillary Surgery. w No Regional Radiation.w No Local-regional Recurrences.
Wong et al Int J Radiat Oncol Biol Phys 2008; 72:866-70.
11
BCS + RT: Sentinel Node Positive
Nomograms –so Y2K!
12
BCS + RT: Sentinel Node Positivew ACSOG Z0011w 891 patients with positive SNBw Clinical T1/T2, Clinical N0w H&E detected metastases in 1-2 nodesw No ECEw Breast tangents only
Giuliano et al JAMA 2011;305:569-75.
•Additional nodal metastases in 27% of patients having completion node dissection.•98% Systemic Therapy (58% chemo)
•Local-regional recurrence 3.3% without completion dissection4.3% with completion dissectionP=0.28
The end of nomograms?
13
14
NCIC CTG MA.20w 2000-2007 with median 62 months follow-up w 1832 patients with high risk node negative (T3) or node
positive breast cancer.w 1-3+ Nodes 85%
w OS 92.3% vs 90.7% (HR .76, p = .07) w LR DFS 96.8% vs 94.5% (HR.59, p.02)w DFS 89.7% vs 84 % (HR .68, p = .003) Whelan et al
ASCO 2011
15
Early Breast Cancer Trialists’ Collaborative Group
Lancet 2005; 366: 2087–2106.
Risk factors for local-regional recurrence after mastectomy
17
Audience Surveyw 1. Which of the following is the strongest indication for adding
postmastectomy radiation with 2 positive axillary nodes?
a) Extranodal extensionb) Premenopausalc) 7 nodes dissectedd) Multifocal breast disease
18
Early Breast Cancer Trialists’ Collaborative Groupw High Risk for LRRw Node Positive Breast Cancer
19
Mastectomy N+ Breast Cancer
Locoregional Relapse Survival
w British Columbia Trial
Ragaz et al J Natl Cancer Inst 2005;97:116-26.
20
Mastectomy N 1-3+ Breast Cancer
Overgaard et al Radiother Oncol 2007;82:247-52.
w Danish Trial 82b+C
21
Early Breast Cancer Trialists’ Collaborative Groupw Intermediate Risk for LRR
22
Mastectomy N 1-3+ Breast Cancer
10-yearIsolatedLRR (%)
1-3 Nodes(# pts)
4-7 Nodes(# pts)
8 + Nodes(# pts)
T1 9 (407) 11 (180) 20 (110)
T2 7 (576) 17 (349) 20 (297)
T3 23 (35) 29 (33) 7 (29)
w ECOG
Recht et al J Clin Oncol 1999;17:1689-1700.
23
Mastectomy N 1-3+ Breast Cancer
Recht et al J Clin Oncol 1999;17:1689-1700.
w ECOG
24
Mastectomy N 1-3+ Breast Cancer
0 1-3 4-9 ≥10T1T2T3
61129
71229
92331
171729
≤11.1-22.1-33.1-44.1-5
37
101326
Katz et al J Clin Oncol18:2817-27; 2000
w MDACC
25
Mastectomy N+ Breast Cancerw MDACC
Katz et al Int J Radiat Oncol Biol Phys2001; 50:397-403.
Importance of ≥ 20% positive nodes
26
Mastectomy N 1-3+ Breast Cancer
Taghian et al J Clin Oncol2004;22:4247-54.
# Isol LRR LRR+/-DF1-3 ≤ 2 1,045 6% 11%
2.1-5 1,489 10% 15%> 5 229 8% 11%
4-9 ≤ 2 512 13% 20%2.1-5 982 15% 24%> 5 220 20% 31%
10+ ≤ 2 187 14% 26%2.1-5 500 20% 33%> 5 165 20% 34%
w NSABP
27
Close/Positive Marginsw MGH, Harvard
Jagsi et al Int J Radiat Oncol Biol Phys2005; 62:1035-9.
28
National Comprehensive Cancer Center
29
Young Age
Age # Isol LRR LRR+/-DF20-39 1130 15% 26%40-49 2050 13% 21%50-59 1600 11% 17%60+ 978 10% 14%
p=0.13 p<0.0001
Significant on Multivariate Analysis
w NSABPw Node Positive Breast Cancer
Taghian et al J Clin Oncol2004;22:4247-54.
30
Combinations of Risk Factors
w Risk factors• Menopause status• Node neg vs. pos• 1 -3 vs. 4 + nodes positive• Tumor size• Lymphovascular invasion• Grade
w International Breast Cancer Study Group
Wallgren et al J Clin Oncol2003;21:1205-13.
31
Mastectomy N 1-3+ Breast Cancer w Cleveland Clinicw 1-3 positive nodes
Tendulkar et al Int J Radiat Oncol Biol Phys 2012; 83:e577-81.
32
Extranodal Extension
Gruber et al J Clin Oncol2005; 23:7089-97.
w International Breast Cancer Study Groupw ECE not significant for local-regional recurrence when
number of positive of nodes included in analysis
33
34
Mastectomy for T3N0 Breast Cancerw NSABPw Isolated LRF 7%
Taghian J Clin Oncol 2006;24:3927-32.
35
Mastectomy for T3N0 Breast Cancer
7.6%
21%
Floyd et al Int J Radiat Oncol Biol Phys2006;66:358-64.
w MGH, Harvard, MD Anderson, Yale
36
Multicentric Diseasew MDACC
Katz et al Int J Radiat Oncol Biol Phys2001; 50:735-42.
37
Molecular subtype
Lum A Lum B TNBC Her2
Kyndi et al J Clin Oncol2008; 26:1419-26.
38
w 4 positive axillary lymph nodesw T3 node positive tumorsw T4
w 1-3 positive axillary nodesw T3 node negative tumorsw Limited / no axillary dissectionw Close / positive marginsw Lymphovascular invasionw High gradew Young Agew Gross ECEw Multicentric diseasew Triple Negativew T1 - 2w Node Negativew Margin Negative
High Risk
Definitely RT
Often RT but not always
Intermediate Risk
Sometimes RT but not always
Low Risk
No RT
Indications for PMRT
Regional nodal radiation therapy
40
Classic Supraclavicular Fieldw BordersInferior: Inferior aspect of
clavicular headSuperior: Cricothyroid notchMedial: 1 cm across midline at
sternal notchLateral: Medial border of
humeral head
w Gantry angled 11-12 ° to shield spinal cord
w Block medial to sternocleidomastoid to shield larynx
w Half beam block creates nondivergent inferior edge
41
Single Isocenter Match
Can’t turn collimator but can add MLC if careful about breast/CW PTV
42
2 Isocenter match
Courtesy of R. Iyer
w If field size too longw If collimation desired
43
w Supraclavicular field• D = 3 cm
w PAB• Calculate dose at midplane
depth at isocenter of PAB from supraclavicular field
• Prescribe PAB to raise that midplane dose.
Classic Posterior Axillary Field
44
Classic IMN Electron Field
NCIC MA.20
45
Classic IMN Electron Field
46
IMN Partially Wide Tangents
NCIC MA.20
47
Nodal Contouring
RTOG AtlasNodal Recurrence
w Supraclavicular
48
Nodal Contouring
RTOG AtlasNodal Recurrence
w Axillary Level III
49
Nodal Contouring
RTOG AtlasNodal Recurrence
w Axillary Levels I/II
50
Nodal Contouring
RTOG Atlas
w IMN
Nodal Recurrence
Chen et al Int J Radiat Oncol Biol Phys2013;85:309-14.
51
Nodal Contouringw Supraclavicular and Axillary Level III
52
Nodal Contouringw Axillary Levels I-III
53
Making a Supraclavicular Fieldw Louisville is not the place to try this for the first time!
54
Making a Supraclavicular Field
Breast conservation and radiation after neoadjuvant chemotherapy
56
Rationale for Neoadjuvant ChemotherapywHigh response rates in locally advanced
breast cancer.wUse of primary response as an in vivo
measure of tumor (presumed distant) chemosensitivity.wReduce size of primary tumor to increase
rates of breast-conserving surgery or to improve cosmetic outcome.wEarlier treatment of micrometastatic
disease to improve survival
57
MetaAnalysis of Neoadjuvant Chemotherapy Randomized Trials
Mauri et al J Natl Cancer Inst2005;97:188-94.
58
Importance of pCRw NSABP B-18 and B-27
w pCR is prognostic for survival.
w Increased rate of pCR by• Grade 3• Nonlobular• ER negative• High Ki-67• HER-2 positive
Rastogi et al J Clin Oncol2008;26: 778-785.
59
Concerns about Neoadjuvant Chemotherapy
wClinical staging of primary and axilla.wSurgical technique for conservative
surgery.• Clip tumor prior to chemotherapy• Significance of resection margins?
wObscuring indications for regional nodal and/or postmastectomy radiation.wEffect on local control.
60
MetaAnalysis of Neoadjuvant Chemotherapy Randomized Trials
Mauri et al J Natl Cancer Inst2005;97:188-94.
61
NSABP B-18 Breast Conservation
IBTR (%) as site of 1st treatment failure
Postop Preop# Chemo # Chemo448 7.6 503 10.7 p=0.12
Downstaged Lump initially# to lump # proposed69 15.9 434 9.9 p=0.04
Wolmark et al J Natl Cancer Inst Monogr 2001;30:96-102.
w Modest increase in breast conservation
62
Mechanism of Increased Breast-Conserving Surgery after Neoadjuvant Chemotherapy
Pre-chemo Volume
Post-chemo Volume?
w Decrease in clinical tumor size.w More favorable ratio of tumor to
breast size.
63
Breast Conservation after Neoadjuvant Chemotherapy
w T3 and stage III were independent predictors of LRR.
Cebrecos et al EJSO 36:528-34; 2010
64
Local Recurrence after Neoadjuvant Chemotherapy
Mamounas et al J Clin Oncol2012;30:3960-6.
w NSABP B-18 and B-27. No Regional Nodal Irradiation.
Let’s add the s’clav field atleast!
Let’s add a boost!
65
Breast Conservation after Neoadjuvant Chemotherapy
w NSABP B-18 and B-27w Breast-conserving surgery and whole breast radiationw No regional nodal radiation
Mamounas et al J Clin Oncol2012;30:3960-6.
Indications for radiation after neoadjuvant chemotherapy and mastectomy
67
Neoadjuvant Chemotherapy and Mastectomy
Buchholtz et al J Clin Oncol2002;20:17-23.
w MDACCw Generally cT3 or pN+ indications for PMRT
68
Clinical T3N0
Nagar et al Int J Radiat Oncol Biol Phys2011;81:782-7.
0/13 complete breast and nodal pCR LRR – need more data
Nodal ypN0Nodal ypN+
69
Neoadjuvant Chemotherapy and Mastectomy
Mamounas et al J Clin Oncol2012;30:3960-6.
w NSABP B-18 and B-27w No PMRT
Do clinically N+ but yp N-need radiation?
70
Neoadjuvant Chemotherapy and Mastectomyw NSABP B-18 and B-27w No postmastectomy radiation
Mamounas et al J Clin Oncol2012;30:3960-6.
RT for pN+
?cN+ and ypN-need more data
Radiation Therapy for Locally Advanced Noninflammatory Breast Cancer
72
Noninflammatory LABC
LABC
T4 Noninflammatory
N2 Axillary Disease
N3 Supraclavicular
Disease
N3 Internal Mammary Disease
73
Noninflammatory LABC
Neoadjuvant Chemotherapy +/- Trastuzumab
Modified Radical Mastectomy
+/- Endocrine Therapy / Trastuzumab
Postmastectomy Radiation
wLocal-regional control 85 - 95%
74
Noninflammatory LABC - PMRT
Huang et al J Clin Oncol2004;22:4691-9.
w MDACC
75
Noninflammatory LABC - PMRT
Heuts et al The Breast2009;18:254-8.
76
Noninflammatory LABC - Breast Conservation
Chen et al J Clin Oncol2004;22:2303-12.
w MDACCw Resolution of skin / chest wall involvement.w Tumor < 5 cm, no multicentric disease or diffuse calcs.
Accept T4 with caution!
Radiation therapy for inflammatory breast cancer
78
Audience Surveyw 2. What is the most important prognostic factor for prognosis
in inflammatory breast cancer?
a) Dermal lymphatic invasionb) Response to chemotherapyc) Estrogen receptor positivityd) Palpable axillary adenopathy
79
Inflammatory LABCw Clinical findings:
• Rapid onset• Peau D’orange > 1/3 of the breast.
w Clinical diagnosis of inflammatory BUT pathology is needed!• Core biopsy of a node• Skin punch biopsy• Breast incisional biopsy
w Dermal lymphatic invasion is not required for diagnosis.w Not to be confused with a locally advanced neglected cancer.
80
Management of Inflammatory LABC
Neoadjuvant Chemotherapy
Second Line Chemotherapy if < cCR
Preop Radiation if < cCR
Modified radical mastectomy
+/- Endocrine Therapy / Trastuzumab
Postmastectomy radiation
81
Inflammatory LABC – Breast Conservation
82
Inflammatory LABC
Harris et al Int J Radiat Oncol Biol Phys2003;55:1200-8.
CW / Breast 50 GyBolusSupraclav in allAxilla in mostIMN in few
w PENN
83
Inflammatory LABCw MSKCC
Damast et al Int J Radiat Oncol Biol Phys2010;77:1105-12.
CW 5,040 Gy Bolus Daily
84
Inflammatory LABCw MDACCw Dose escalation for < partial chemotherapy response,
close/positive margins, and age < 45 years
Bristol et al Int J Radiat Oncol Biol Phys2008;72:474-84.
CW 50 Gy + 10 Gy Boost or 51 Gy BID + 15 Gy BoostComprehensive nodal RT
85
Audience Surveyw 3. A 60 year old woman is treated with breast-conserving
surgery for ER+, <5cm, invasive breast cancer. In which of the following situations is it acceptable to proceed with adjuvant radiation therapy WITHOUT axillary lymph node dissection (ALND)?
a) Sentinel lymph node biopsy (SLNB) reveals 1 lymph node with micrometastasis and the patient had clinically suspicious axillary nodes on preoperative ultrasound.b) SLNB shows isolated tumor cells in 1 SLN and axilla were clinically negative.c) The patient has 1 positive SLN, clinically negative axilla and will receive partial breast irradiation.d) The patient has 2 positive SLNs, clinically negative axilla and declines chemotherapy.e) It is never acceptable to omit ALND.